Johnson & Johnson's Invokana closes in on badly needed kidney disease nod with FDA 'priority' boost

Invokana
If approved in chronic kidney disease, Invokana could be the first Type 2 diabetes therapy to win such a green light. (Johnson & Johnson)

When it comes to Invokana sales, Johnson & Johnson needs a way to stop the bleeding. And it just got one step closer to a new indication that could do just that.

The FDA granted the drug a priority review in patients with diabetes and chronic kidney disease (CKD), based on an outcomes trial showing Invokana could cut disease and death risks. The move sets the drug up for a speedy approval and a shot at a sales boost later this year.

RELATED: Invokana win in kidney patients could help J&J right the SGLT2 ship

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

If the agency approves the new use, J&J could market Invokana to cut the risk of end-stage kidney disease and kidney-related or cardiovascular death in patients with both Type 2 diabetes and CKD. That's a distinction its rivals don't now have, and one that could help counterbalance a safety warning that other SGLT2 drugs don't have, either.

Regulators based their decision on phase 3 data showing Invokana, combined with standard-of-care treatment, topped the standard of care alone at staving off kidney disease progression. The SGLT2 drug also slashed the risk of cardiovascular death and heart failure-related hospitalizations by 31%.

The data represent a “huge advance” for patients, Jim List, cardiovascular head at J&J’s Janssen, said at the time.

RELATED: Johnson and Johnson's Invokana matches Jardiance's 14% reduction in major CV events—but doubles amputation risk, too

They also represent a chance for J&J to get a jump on its competitors, which are studying their own SGLT2 drugs in kidney disease. AstraZeneca in 2016 launched a Phase IIIb study of its Farxiga in CKD, while partners Boehringer Ingelheim and Eli Lilly in 2017 rolled out plans to start a similar outcomes study for their contender, Jardiance.

If approved, though, Invokana would be the first of the group—and the first diabetes med in general—to treat CKD in patients with Type 2 diabetes, J&J noted, and that distinction could result in some much-needed sales firepower.

The drug has been suffering in the diabetes arena thanks to a boxed warning detailing its increased risk of lower-limb amputations. A delay on its heart-helping approval—doled out on the back of positive CV outcomes data—didn't help its prospects. 

Last year, Invokana sales sunk to $881 million from $1.4 billion back in 2016. And the damage has continued through early 2019, with Q1 sales of $154 million marking a 25% slide from the same period a year prior.

Suggested Articles

A manufacturing facility that Novartis discarded because of declining generics sales is getting a new life producing CBD products.

Allergan investors have been pushing for action from management, and AbbVie has been hunting for new revenue streams. Now, they're set to combine.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.